SCHEMBL5072274

SCHEMBL5072274

CCCCC(c1cnc(-c2ccccc2)n1CCCC)N(Cc1ccccc1)Cc1ccc(O)cc1Cl

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.35
PDK1 Q15118 6/20 0.33
C5AR1 P21730 1/20 0.33
HSP90AA1 P07900 1/20 0.32
PDK2 Q15119 1/20 0.32
PDK4 Q16654 1/20 0.32
KMT2A Q03164 2/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
GAA P10253 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
ESR1 P03372 1/20 0.31
BRD4 O60885 1/20 0.30
UBE2M P61081 1/20 0.30
DCUN1D1 Q96GG9 1/20 0.30
PDE4B Q07343 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5073855 0.92 TSHR (0.36) TSHRC5AR1KMT2AKDM4EMEN1
SCHEMBL5134566 0.88 TSHR (0.41) TSHRPDK1C5AR1KMT2AKDM4E
SCHEMBL5134818 0.87 TSHR (0.39) TSHRPDK1C5AR1PDE4B
SCHEMBL5135314 0.86 CXCR3 (0.33) TSHRC5AR1ESR1
SCHEMBL5136624 0.83 TSHR (0.40) TSHRC5AR1KDM4EALDH1A1SMN1; SMN2
SCHEMBL5136271 0.83 MEN1 (0.37) PDK1KMT2AKDM4EMEN1UBE2M
SCHEMBL5136148 0.82 OPRK1 (0.40) TSHRC5AR1PDE4B
SCHEMBL5137355 0.82 TSHR (0.39) TSHRC5AR1PDE4B
SCHEMBL5135509 0.80 TSHR (0.38) TSHRPDK1C5AR1KMT2AKDM4E
SCHEMBL5134768 0.80 TSHR (0.41) TSHRC5AR1KMT2AKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed